Advertisement

Journal of Neuro-Oncology

, Volume 140, Issue 2, pp 477–483 | Cite as

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma

  • Jennie W. Taylor
  • Mili Parikh
  • Joanna J. Phillips
  • C. David James
  • Annette M. Molinaro
  • Nicholas A. Butowski
  • Jennifer L. Clarke
  • Nancy Ann Oberheim-Bush
  • Susan M. Chang
  • Mitchel S. Berger
  • Michael Prados
Clinical Study

Abstract

Introduction

Alterations in the CDK4/6—RB signaling pathway are common causes of cell cycle dysregulation in many cancers, including glioblastoma. Palbociclib is an oral inhibitor of CDK4/6, which leads to phosphorylation of RB1 and cell-cycle arrest. We conducted a two-arm study evaluating efficacy and tissue pharmacokinetics/pharmacodynamics of palbociclib in patients with recurrent glioblastoma.

Methods

Eligibility criteria included confirmation of RB1 proficiency by IHC; ≤ 3 relapses; KPS ≥ 60; no limit on prior treatments. Arm 1 received palbociclib for 7 days prior to indicated resection followed by adjuvant palbociclib. Arm 2 received palbociclib without resection. Primary objective was PFS6; secondary included toxicity, OS, and ORR. Exploratory aims included biomarker assessment and pharmacokinetic/pharmacodynamic effects in surgical patients.

Results

Total of 22 patients were enrolled; 6 on Arm 1 and 16 on Arm 2. Trial was stopped early secondary to lack of efficacy, with 95% of evaluable patients progressing within 6 months. Median PFS was 5.14 weeks (range 5 days–142 weeks) and median OS was 15.4 weeks (range 2–274 weeks). Two patients (10%) had related grade ≥ 3 AEs. In Arm 1, 5 patients had tissue concentrations of palbociclib felt to be sufficient for biological effect and paired samples available for RB1 IHC. There were no consistent changes in RB1 expression or cell proliferation in the paired tissue.

Conclusion

In this trial, despite adequate tissue PK, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma. However, these were heavily pretreated patients and targeting the CDK4/6 pathway may still deserve further exploration.

Keywords

Palbociclib Recurrent glioblastoma CDK4/6 inhibitor Retinoblastoma pathway 

Notes

Funding

Support for this study was provided by Pfizer (M.P.), National Cancer Institute P50CA097257 (M.P. and C.D.J), R01CA159467 (C.D.J.) and the Accelerated Brain Cancer Cure (ABC2) (M.P.).

Compliance with ethical standards

Conflict of interest

All authors report no conflicts of interest relevant to this study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefGoogle Scholar
  2. 2.
    Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefGoogle Scholar
  3. 3.
    Friedman HS et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740CrossRefGoogle Scholar
  4. 4.
    Kreisl TN et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745CrossRefGoogle Scholar
  5. 5.
    Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153–166CrossRefGoogle Scholar
  6. 6.
    Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068CrossRefGoogle Scholar
  7. 7.
    Michaud K et al (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70(8):3228–3238CrossRefGoogle Scholar
  8. 8.
    Finn RS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936CrossRefGoogle Scholar
  9. 9.
    Wen PY et al (2010) Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 12(1):68–75CrossRefGoogle Scholar
  10. 10.
    Goldhoff P et al (2012) Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. J Neuropathol Exp Neurol 71(1):83–89CrossRefGoogle Scholar
  11. 11.
    Clarke JL et al (2011) Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 13(10): 1118–1124CrossRefGoogle Scholar
  12. 12.
    Lamborn KR et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162–170CrossRefGoogle Scholar
  13. 13.
    PD-0332991 Investigator’s Brocure. 2010Google Scholar
  14. 14.
    Chinot OL et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722CrossRefGoogle Scholar
  15. 15.
    Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708CrossRefGoogle Scholar
  16. 16.
    Hashizume R et al (2016) Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol 18:1519–1528Google Scholar
  17. 17.
    Sherr CJ, Beach D, Shapiro GI (2016) Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 6(4):353–367CrossRefGoogle Scholar
  18. 18.
    Huillard E et al (2012) Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci USA 109(22):8710–8715CrossRefGoogle Scholar
  19. 19.
    Hashizume R et al (2016) Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol 18(11):1519–1528Google Scholar
  20. 20.
    Goel S et al (2017) CDK4/6 inhibition triggers anti-tumour immunity. Nature 548(7668):471–475CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jennie W. Taylor
    • 1
    • 2
  • Mili Parikh
    • 1
  • Joanna J. Phillips
    • 1
    • 4
  • C. David James
    • 5
  • Annette M. Molinaro
    • 1
    • 3
  • Nicholas A. Butowski
    • 1
  • Jennifer L. Clarke
    • 1
    • 2
  • Nancy Ann Oberheim-Bush
    • 1
    • 2
  • Susan M. Chang
    • 1
  • Mitchel S. Berger
    • 1
  • Michael Prados
    • 1
  1. 1.Department of Neurological SurgeryUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Department of NeurologyUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Department of Epidemiology & BiostatisticsUniversity of California at San FranciscoSan FranciscoUSA
  4. 4.Division of Neuropathology, Department of PathologyUniversity of California, San FranciscoSan FranciscoUSA
  5. 5.Department of Neurological Surgery, Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations